Skip to main content
. 2013 Feb 27;8(2):e57796. doi: 10.1371/journal.pone.0057796

Figure 3. IL-1β decreases RBP4 production.

Figure 3

SGBS adipocytes were treated with increasing doses of IL-1β (0.05, 0.5, 5, 50 ng/ml) or the corresponding vehicle control. (A) RBP4 mRNA expression was measured by quantitative PCR. RBP4 expression was normalized to succinate dehydrogenase complex subunit A (SDHA) and related to medium control using 2−ΔΔCT method. Data are presented as mean+SEM of three independent experiments. *p<0.05 (treatment vs. vehicle). (B) Accumulation of RBP4 in the medium supernatant was measured by ELISA. Measurements were related to untreated medium control. Data are presented as mean+SEM of three independent experiments. *p<0.05 (treatment vs. vehicle). (C, D) Human primary adipocytes obtained from three different donors were treated with 5 ng/ml of IL-1β or vehicle. (C) mRNA expression and (D) secretion of RBP4 was performed as described above.*p<0.05 (treatment vs. vehicle). (E) SGBS adipocytes were treated with 5 ng/ml of IL-1β for 24, 48, and 72 hours. mRNA expression of RBP4 was measured by quantitative PCR. RBP4 expression was normalized to SDHA and related to medium control at 0 hours using 2−ΔΔCT method. *p<0.05 (treatment vs. vehicle).